Zie ook in gerelateerde artikelen voor meer artikelen over parpremmers bij eierstokkanker

4 oktober 2019: Bron: NEJM

Wanneer patienten met nieuwe diagnose van uitgezaaide eierstokkanker naast chemo de parpremmer niraparib krijgen en vervolgens als onderhoudsbehandeling alleen niraparib dan verdubbelt de mediane overall overleving in vergelijking met een placebo. (22 months niraparib vs 10 months placebo; HR, 0.43)

Ik vertaal maar niet verder want het abstract van deze studie: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer is verder wel duidelijk lijkt mij.

ORIGINAL ARTICLE

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

  • Antonio González-Martín, M.D., Ph.D., 
  • Bhavana Pothuri, M.D., 
  • Ignace Vergote, M.D., Ph.D., 
  • René DePont Christensen, Ph.D., 
  • Whitney Graybill, M.D., 
  • Mansoor R. Mirza, M.D., 
  • Colleen McCormick, M.D., M.P.H., 
  • Domenica Lorusso, M.D., Ph.D., 
  • Paul Hoskins, M.D., 
  • Gilles Freyer, M.D., 
  • Klaus Baumann, M.D., 
  • Kris Jardon, M.D., 
  •  for the PRIMA/ENGOT-OV26/GOG-3012 Investigators*

Abstract

BACKGROUND

Niraparib, an inhibitor of poly(adenosine diphosphate –ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy, regardless of the presence or absence of BRCA mutations. The efficacy of niraparib in patients with newly diagnosed advanced ovarian cancer after a response to first-line platinum-based chemotherapy is unknown.

METHODS

In this randomized, double-blind, phase 3 trial, we randomly assigned patients with newly diagnosed advanced ovarian cancer in a 2:1 ratio to receive niraparib or placebo once daily after a response to platinum-based chemotherapy. The primary end point was progression-free survival in patients who had tumors with homologous-recombination deficiency and in those in the overall population, as determined on hierarchical testing. A prespecified interim analysis for overall survival was conducted at the time of the primary analysis of progression-free survival.

RESULTS

Of the 733 patients who underwent randomization, 373 (50.9%) had tumors with homologous-recombination deficiency. Among the patients in this category, the median progression-free survival was significantly longer in the niraparib group than in the placebo group (21.9 months vs. 10.4 months; hazard ratio for disease progression or death, 0.43; 95% confidence interval , 0.31 to 0.59; P<0.001). In the overall population, the corresponding progression-free survival was 13.8 months and 8.2 months (hazard ratio, 0.62; 95% CI, 0.50 to 0.76; P<0.001). At the 24-month interim analysis, the rate of overall survival was 84% in the niraparib group and 77% in the placebo group (hazard ratio, 0.70; 95% CI, 0.44 to 1.11). The most common adverse events of grade 3 or higher were anemia (in 31.0% of the patients), thrombocytopenia (in 28.7%), and neutropenia (in 12.8%). No treatment-related deaths occurred.

CONCLUSIONS

Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival than those who received placebo, regardless of the presence or absence of homologous-recombination deficiency. (Funded by GlaxoSmithKline; PRIMA/ENGOT-OV26/GOG-3012 ClinicalTrials.gov number, NCT02655016. opens in new tab.)


Plaats een reactie ...

Reageer op "Parpremmer niraparib naast chemo en daarna als onderhoudsbehandeling verdubbelt mediane overall overleving in vergelijking met placebo"


Gerelateerde artikelen
 

Gerelateerde artikelen

Parpremmer niraparib naast >> Parpremmer Veliparib naast >> niraparib plus bevacizumab >> Olaparib als onderhoudsbehandeling >> Olaparib, een PARP remmer, >> Parpremmers Olaparib en niraparib >> Patienten met gevorderde eierstokkanker >> Parpremmer rucaparib verdubbelt >> Niraparib geeft zeer goede >> Olaparib plus cedinarib lijkt >>